Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118754 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase 1 study of Dry Eye, sponsored by Santen.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 10
- Study locations
NCT01118754: Completed Phase 1 study of Dry Eye, sponsored by Santen.
NCT01118754 is a Phase 1 study of Dry Eye that has completed, run by Santen. The registered enrollment target is 132 participants, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (42% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01118754, a Phase 1 study of Dry Eye, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
Conditions Studied
Interventions
- DRUG DE-101 ophthalmic suspension
- DRUG DE-101 ophthalmic suspension vehicle
Study Locations (10)
California
- - Inglewood
- - Torrance
Indiana
- - Indianapolis
- - New Albany
Connecticut
- - Bloomfield
Louisiana
- - Gretna
Maine
- - Bangor
Ohio
- - Cleveland
Pennsylvania
- - Philadelphia
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT01118754 record still lists
NCT01118754 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which DE-101 ophthalmic suspension is the first listed.
NCT01118754 lists 10 locations in 8 states (California, Indiana, Connecticut).
Frequently Asked Questions
What is clinical trial NCT01118754 about?
NCT01118754 is a clinical study titled "Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients". The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
What is the current status of trial NCT01118754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2010-04. Estimated completion is 2010-12.
What conditions does trial NCT01118754 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT01118754?
The interventions under investigation include: DE-101 ophthalmic suspension (DRUG), DE-101 ophthalmic suspension vehicle (DRUG).
Who is sponsoring clinical trial NCT01118754?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01118754 being conducted?
This trial has 10 study locations across California, Connecticut, Indiana, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01118754's enrollment target sits among peer trials
132 8th of 41 higher than 34 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
COMPLETED · Phase 1
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
The THINK Study Incidence of Neurotrophic Keratopathy)
RECRUITING · NA
-
Low Level Light Therapy & Skin Pigmentation
RECRUITING · NA
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia